Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: A randomised controlled trial

Vaccine

Volumn 25, Issue 15, 2007, Pages 2817-2822

  Heron, Leon ^a   Selnikova, Olga ^b   Moiseieva, Anna ^b   Van Damme, Pierre ^c   van der Wielen, Marie ^c   Levie, Karin ^d   Hoet, Bernard ^e   Stoffel, Michel ^e  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b State Enterprise Center of Immunobiological preparations   (Ukraine)

^c Centre for the Evaluation of Vaccination   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adolescents; Hepatitis B vaccine; Vaccine schedules

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE;

ADOLESCENT; CHILD; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; SINGLE-BLIND METHOD; VACCINES, SYNTHETIC;

EID: 33947097851     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.021     Document Type: Article

References (29)

1. Hoofnagle J.H. Chronic hepatitis B. N Engl J Med 323 5 (1990) 337-339
2. Coleman P.J., McQuillan G.M., Moyer L.A., Lambert S.B., and Margolis H.S. Incidence of hepatitis B virus infection in the United States 1976-1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 178 (1998) 954-959
3. Tepper M.L. Universal hepatitis B vaccination: young adolescent immunization. Vaccine 16 Suppl. (1998) S23-S26
4. WHO. Hepatitis B vaccines. Wkly Epidemiol Rec 79 (2004) 255-263
5. CDC. Hepatitis B factsheet. http://www.cdc.gov/ncidod/diseases/hepatitis/b/bfact.pdf.
6. Alter M.J., Hadler S.C., Margolis H.S., Alexander W.J., Hu P.Y., Judson F.N., et al. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA 263 (1990) 1218-1222
7. Hyams K.C. Risk of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 20 (1995) 992-1000
8. ACIP task force on adult immunization and infectious diseases society of America. Guide for adult immunization, 3rd ed. Philadelphia, PA: American College of Physicians; 1994, p. x-xi.
9. Centers for Disease Control. Immunization of adolescents. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Practice, and the American Medical Association. MMWR Morb Mortal Wkly Rep 45 RR-13 (1996) 1-16
10. Society for Adolescent Medicine. Position statement on hepatitis B immunization. J Adolesc Health 17 (1995) 256
11. World Health Organization. Expanded programme on immunization. Global Advisory Group-Part I. Wkly Epidemiol Rec 67 (1992) 11-15
12. Francois G., Hallauer J., and Van Damme P. Hepatitis B vaccination: how to reach risk groups. Vaccine 21 1-2 (November) (2002) 1-4
13. Wong V.K., Woodruff C., and Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Pediatr Infect Dis J 13 (1994) 936
14. Immergluck L.C., Willis F.E., and McCarthy C.A. Evaluation of the acceptance of the hepatitis B vaccination in urban adolescents. Arch Pediatr Adolesc Med 148 Suppl. (1994) 120 [abstract]
15. Kottenhahn R.K., Rosenthal S.L., and Biro F.M. Hepatitis B vaccine completion among adolescents. Del Med J 68 (1996) 309-311
16. Middleman A.B., Robertson L.M., Young C., Durant R.H., and Emans S.J. Predictors of time to completion of the hepatitis B vaccination series among adolescents. J Adolesc Health 25 (1999) 323-327
17. Hepatitis B vaccination of adolescents-California, Louisiana, and Oregon, 1992-1994. MMWR Morb Mortal Wkly Rep 1994;43:605-609.
18. Wistrom J., Ahlm C., Lundberg S., Settergren B., and Tarnvik A. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 17 17 (1999) 2162-2165
19. Cassidy W.M., Watson B., Ioli V.A., Williams K., Bird S., and West D.J. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107 (2001) 626-631
20. Heron L.G., Chant K.G., and Jalaludin B.B. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 20 (2002) 3465-3471
21. Australian immunisation handbook, 8th ed., 2003. Section 3.9 Hepatitis B. Available at: http://www9.health.gov.au/immhandbook/.
22. Centers for Disease Control. Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11-15 years. MMWR 49 (2000) 261
23. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., and Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1 (1981) 377-385
24. Francis D.P., Hadler S.C., Thompson S.E., Maynard J.E., Ostrow D.G., Altman N., et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 97 (1982) 362-368
25. Centers for Disease Control. Recommendation of the Immunization Practices Advisory Committee (ACIP). Recommendations for protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 34 (1985) 313-324 329-335
26. Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee. Update on hepatitis B prevention. MMWR Morb Mortal Wkly Rep 36 (1987) 353-360 366
27. International Group. Immunisation against hepatitis B. Lancet 1 (1988) 875-876
28. World Health Organization. Informal consultation on quadrivalent diphtheria-tetanus-pertussis-hepatitis vaccine. Final Report. Geneva, Switzerland: World Health Organization; 1992.
29. Levaux H.P., Schonfeld W.H., Pellissier J.M., Cassidy W.M., Sheriff S.K., and Fitzsimon C. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents. Pediatrics 108 (2001) 317-325